Benaglutide Injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Brand: Yishengtai
Company: Shanghai Benemae Pharmaceutical
Medicine type: Biologic
Therapeutic area: Endocrinology & metabolism
Indications recorded in the public source: (1) For glycemic control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with metformin alone. (2) As an adjunct to diet and exercise, for weight management in adults with BMI at least 28 kg/m2, or BMI at least 24 kg/m2 with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, fatty liver or obstructive sleep apnea syndrome.
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Not matched in the 2025 national list; manual review pending
Insurance edition: 2025 edition; effective 1 January 2026
Insurance verification notes: No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions